Takeda, Intra-Cellular Ink Global Co-Development Deal For PDE1 Inhibitors For Schizophrenia

TOKYO and NEW YORK - Osaka-based Takeda Pharmaceutical Co. and New York-based Intra-Cellular Therapies announced March 3 a global co-development deal for selective phosphodiesterase type 1 inhibitors discovered by Intra-Cellular for treatment of cognitive impairment associated with schizophrenia